Prabhudas Lilladher has reiterated a BUY call on Sun Pharmaceutical Industries, setting a target price of Rs 2,070 versus a current market price of Rs 1,845. The broker’s latest Q4FY26 update says the company remains on a durable growth path, even though operating profit missed estimates because of higher expenses. Revenue rose 13% year on year to Rs 146.1 billion, helped by robust domestic sales, a stronger specialty portfolio, and healthy traction in rest-of-world markets. The larger story is that Sun Pharma is gradually changing its earnings engine: dependence on US generics is fading, while domestic pharma, specialty drugs, and newer launches are taking the lead. The Organon acquisition, if completed as expected in Q4FY27E, could further deepen that transition.

Revenue engine stays broad-based

Top-line growth was the quarter’s clearest strength. Consolidated net sales came in at Rs 146.1 billion, slightly ahead of estimates, and rose across the key operating verticals. Domestic formulations grew 15% year on year, global specialty sales climbed 20%, rest-of-world markets increased 16%, and emerging markets expanded 24%; API sales also grew 26%. US sales were softer sequentially at USD 459 million, but the bigger picture remained constructive because innovative medicines are now offsetting weaker generic performance.

Sun Pharma’s domestic business continues to gain share and momentum. The company reported 6% volume growth, launched 11 new products in the quarter, and lifted market share in the Indian pharma market to 8.4% from 8.1%, the strongest gain since the Ranbaxy acquisition. Management also highlighted encouraging physician response to semaglutide injections, which could add another meaningful leg to growth.

Margins felt the pressure

EBITDA growth lagged because operating costs moved up faster than sales. Reported EBITDA rose just 3% year on year to Rs 35.3 billion, below the broker’s estimate of Rs 37.6 billion. The operating margin fell to 24.1% from 26.4% a year ago and 30.9% in the previous quarter, reflecting higher employee costs, elevated other expenses, and seasonality in some products. R&D intensity stayed elevated at 6.7% of sales, which is not a surprise for a company leaning into innovation, but it did weigh on near-term profitability.

Gross margin stayed healthy at 80.8%, which suggests pricing and product mix remain solid. Still, the quarter makes one thing clear: Sun Pharma’s growth story is no longer just about sales; it now depends on how efficiently the company converts that sales momentum into operating leverage.

Specialty portfolio leads the story

The market is increasingly rewarding Sun Pharma’s shift toward specialty and branded assets. In the US, specialty sales crossed USD 1 billion in FY26, and the company said its innovative medicines business is now larger than its generics business there. Key drivers included Winlevi, Ilumya, Cequa, and Odomzo, while Unloxcyt has received a positive physician response and is seeing repeat orders from cancer centers and infusion facilities. These are exactly the kind of assets that can support premium valuations over time.

The company also received USFDA acceptance for the Ilumya BLA in psoriatic arthritis, with an action date set for October 2026. Management retained its high-single-digit revenue growth guidance for FY27E and guided R&D spend at 6%-7% of sales, which signals continued investment rather than short-term margin optimization.

Organon could sharpen the mix

The acquisition of Organon is the strategic wildcard investors should watch. Management described the portfolio as highly complementary, with minimal overlap, and the deal is expected to expand Sun Pharma’s branded and innovative medicine footprint. The company said the combined innovative medicines contribution could rise to 26%-27% after the acquisition, giving the business a richer mix and potentially more resilient earnings.

The broker believes the acquisition is EPS-accretive from year one and should deliver meaningful long-term accretion, though the real test will be execution. If Sun Pharma grows the acquired assets faster than their historical run-rate, the stock could justify even higher multiples; if not, some of the excitement may fade. The note pegs the acquisition closure in Q4FY27E.

What the numbers imply

Prabhudas Lilladher’s revised model points to stronger earnings ahead despite the quarterly miss. The broker now expects FY27E sales of Rs 657.0 billion and FY28E sales of Rs 725.6 billion. EBITDA is projected at Rs 192.3 billion in FY27E and Rs 219.6 billion in FY28E, with margin expansion toward 30.3% by FY28E. EPS is estimated at Rs 56.7 for FY27E and Rs 65.3 for FY28E.

The stock is valued at 32.5x FY27E EPS and 28.3x FY28E EPS, which is demanding but not unusual for a high-quality pharma franchise with specialty exposure and strong cash generation. The target price of Rs 2,070 is based on 23x FY28E combined-entity EPS, implying the broker sees room for upside as the specialty mix deepens.

Levels for investors

For investors tracking the stock, the immediate reference points are clear. CMP stands at Rs 1,845, which means the broker’s target of Rs 2,070 offers roughly 12% upside from current levels. A near-term support zone appears around Rs 1,800 to Rs 1,750, where the stock has previously shown resilience, while the 52-week low of Rs 1,547 provides a deeper structural floor. On the upside, Rs 1,917, the 52-week high, is the first obvious breakout checkpoint, and a sustained move above that could improve momentum.

Investment view

Sun Pharma remains a premium pharmaceutical compounder, but it now has to prove that premium with execution. The company has built a more diversified earnings base, enjoys a strong balance sheet, and continues to benefit from specialty-led growth in the US and domestic market share gains in India. At the same time, the quarter showed that margin expansion will not be linear, especially with higher opex and sustained R&D spending.

For long-term investors, the case rests on three pillars: sustained domestic traction, continued specialty momentum, and a successful Organon integration. If those pieces align, the stock’s valuation can remain elevated and the target may still prove conservative.